Hepatocellular carcinoma in Budd-Chiari syndrome: Characteristics and risk factors

Gut

Volumn 57, Issue 6, 2008, Pages 828-835

  Moucari, R ^a   Rautou, P E ^a   Cazals Hatem, D ^a   Geara, A ^a   Bureau, C ^b   Consigny, Y ^a   Francoz, C ^a   Denninger, M H ^a   Vilgrain, V ^a   Belghiti, J ^a   Durand, F ^a   Valla, D ^a   Plessier, A ^a  

^a BEAUJON HOSPITAL   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTICLE; BUDD CHIARI SYNDROME; CANCER INCIDENCE; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INFERIOR CAVA VEIN OBSTRUCTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER NODULE; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO;

ADULT; ALGORITHMS; ALPHA-FETOPROTEINS; BIOPSY; BUDD-CHIARI SYNDROME; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SEX FACTORS;

EID: 44149112830     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.139477     Document Type: Article

References (48)

1. Di Bisceglie AM, Carithers RL, Gores GJ. Hepatocellular carcinoma. Hepatology 1998;28:1161-5.
2. El Serag HB, Mason AC. Raising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
3. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003;38:793-803.
4. Janssen H, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
5. Menon N, Shah V, Kamah PS. The Budd-Chiari syndrome. N Engl J Med 2004;350:578-85.
6. Nakamura T, Nakamura S, Aikawa T, et al. Obstruction of the inferior vena cava in the hepatic portion and the hepatic veins. Angiology 1968;19:479-98.
7. Takeuchi J, Takada A, Hasumura Y, et al. Budd-Chiari syndrome associated with obstruction of the inferior vena cava. Am J Med 1971;51:11-20.
8. Espana P, Figuera D, Fernadez de Miguel JM, et al. Membranous obstruction of the inferior vena cava and hepatic veins. Budd-Chiari syndrome? A treatable disease. Am J Gastroenterol 1980;73:28-32.
9. Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982;82:171-8.
10. Ono J, Sakoda K, Kawada T, et al. Long-term follow-up result of portopulmonary shunt by splenopneumopexy on membranous obstruction of the inferior vena cava. Surgery 1984;95:116-9.
11. Kage M, Arakawa M, Kojiro M, et al. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992;102:2081-90.
12. Rector W, Xu Y, Goldstein L, et al. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985;64:134-43.
13. Kew MC, McKnight A, Hodkinson J, et al. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in southern African blacks. Hepatology 1989;9:121-5.
14. Daniele B, Bencivenga A, Megna AS, et al. α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-12.
15. Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome. Gut 2006;55:878-84.
16. Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006;44:1308-16.
17. Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003;37:510-9.
18. Vilgrain V, Lewin M, Vons C, et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 1999;210:443-50.
19. Deltenre P, Denninger MH, Hilaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48:264-8.
20. Denninger MH, Chat Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-91.
21. Kamath PS. Budd-Chiari syndrome: radiologic findings. Liver Transplantation 2006;12:S21-2.
22. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorders and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-34.
23. Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90:807-11.
24. Bruix J, Sherman M. Management of hepatocellular carcinoma (AASLD Practice Guideline). Hepatology 2005;42:1208-36.
25. Brancatelli G, Federle MP, Grazioli L, et al. Benign regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation. Radiographics 2002;22:847-62.
26. Maetani Y, Itoh K, Egawa H, et al. Benign hepatic nodules in Budd-Chiari syndrome: radiologic-pathologic correlation with emphasis on the central scar. AJR Am J Roentgenol 2002;178:869-75.
27. Murad SD, Valla DC, De Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-8.
28. Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132-9.
29. Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006;91:1712-3.
30. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-8.
31. Mahmoud AE, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40:798-800.
32. Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
33. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
34. Lu CH, Chou YH, Hwang SJ, et al. Membranous obstruction of inferior vena cava in Taiwan. J Gastroenterol Hepatol 1995;10:287-94.
35. Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996:11:170-9.
36. Okuda K. Membranous obstruction of the inferior vena cava (obliteartive hepatocavopathy, Okuda). J Gastroenterol Hepatol 2001;16:1179-83.
37. Kew MC, Hodkinson HJ. Membranous obstruction of the inferior vena cava and its causal relationship to hepatocellular carcinoma. Liver International 2006;26:1-7.
38. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
39. Valla DC. Hepatic venous outflow obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004;19(Suppl 7):S204-11.
40. Lee BB, Villavicencio L, Kim YW, et al. Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction. J Vasc Surg 2006;43:101-8.
41. Blanshard C, Dodge G, Pasi J, et al. Membranous obstruction of the inferior vena cava in a patient with factor V Leiden: evidence for a post-thrombotic aetiology. J Hepatol 1997;26:731-5.
42. Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998;27:488-96.
43. Williams JH, Phillips TD, Jolly PE, et al. Human aflatoxicosis in developing countries: a review of toxicology, potential health consequences, and interventions. Am J Clin Nutr 2004;80:1106-22.
44. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
45. Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am J Gastroenterol 2003;98:201-4.
46. Shin SH, Chung YH, Suh DD, et al. Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:319-24.
47. Valls C, Cos M, Figueras J, et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dual phase helical CT. AJR Am J Roentgenol 2004;182:1011- 7.
48. Ito K, Fujita T, Shimizu A, et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am J Roentgenol 2004;183:699-705.